Andreas Zoltán Kiss

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Biotransformation of irinotecan (CPT-11) into its pharmacologic active metabolite SN-38 was investigated in patients treated for advanced colorectal cancer. A dose of 180 mg/m(2) CPT-11 was administered to 6 patients by 60 min hepatic intra-arterial infusion (HAI) via a surgically implanted Port-a-Cath® system. Blood samples were collected from 0 to 360 min(More)
The present paper describes an effectiveness-study to analyze the effectiveness of psychotherapeutic treatments. In the documentation phase of three years 24 therapists documented 93 psychotherapies. The patients represent a general population of health care takers. The treatments have an average duration of 45 appointments over 62 weeks. Good results are(More)
3540 Background: The monoclonal antibody (mab) bevacizumab (BEV) inhibits VEGF, downregulates angiogenesis and lowers interstitial pressure, by which blood tissue transfer and metabolism of a drug could be modulated. CPT 11 produced survival benefit combined with BEV and undergoes complex biotransformation by different enzymatic routes: carboxylesterase(More)
BACKGROUND The effect of biweekly cetuximab (CTX) on the pharmacokinetics of CPT-11 and its metabolites was evaluated in this prospective, paired, crossover study. PATIENTS AND METHODS Patients with epidermal growth factor receptor-positive advanced colorectal cancer received infusions of CPT-11 (180 mg/m(2); FOLFIRI schedule) every second week. CTX (500(More)
  • 1